Compare · DXCM vs MOTS
DXCM vs MOTS
Side-by-side comparison of DexCom Inc. (DXCM) and Motus GI Holdings Inc. (MOTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MOTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $22.98B, about 1420.8x MOTS ($16.2M).
- DXCM has hit the wire 8 times in the past 4 weeks while MOTS has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for MOTS).
- Company
- DexCom Inc.
- Motus GI Holdings Inc.
- Price
- $59.53+3.39%
- $0.18-30.42%
- Market cap
- $22.98B
- $16.2M
- 1M return
- -5.19%
- -
- 1Y return
- -15.24%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2018
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Motus GI Holdings Inc.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
Latest MOTS
- Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form EFFECT filed by Motus GI Holdings Inc.
- SEC Form 15-12G filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.
- SEC Form S-8 POS filed by Motus GI Holdings Inc.